BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 8011013)

  • 1. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA; Gardner GD
    Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
    Dhople AM; Namba K
    Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
    Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
    Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of rifabutin against Mycobacterium leprae.
    Yoder LJ; Jacobson RR; Hastings RC
    Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity of rifabutin against Mycobacterium leprae in armadillos.
    Dhople AM; Williams SL
    Int J Antimicrob Agents; 1997 Jan; 9(3):169-73. PubMed ID: 9552713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
    Dhople AM; Lamoureux LC; Gardner GD
    Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
    Dhople AM; Ortega I; Seydel JK; Gardner GD
    Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    Southeast Asian J Trop Med Public Health; 1997 Dec; 28(4):803-10. PubMed ID: 9656405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice.
    Tomioka H; Saito H
    Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):250-4. PubMed ID: 8396614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
    Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
    Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer drugs in leprosy.
    Grosset JH
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

  • 17. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
    Dhople AM; Namba K
    J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New WHO recommendations for the treatment of leprosy].
    Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    Indian J Lepr; 1995; 67(4):375-82. PubMed ID: 8849914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistant Mycobacterium leprae from patients with leprosy.
    Maeda S; Matsuoka M; Nakata N; Kai M; Maeda Y; Hashimoto K; Kimura H; Kobayashi K; Kashiwabara Y
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3635-9. PubMed ID: 11709358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.